Business
miRagen Strengthens Leadership Team with Appointment of Lee Rauch as Chief Operating Officer
BOULDER, Colo., June 18, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"BOULDER, Colo., June 18, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the appointment of Lee Rauch as Chief Operating Officer, effective immediately. Ms. Rauch reports directly to President and Chief Executive Officer William S. Marshall, Ph.D., and is responsible for overseeing miRagen’s business development, licensing, partnerships, investor relations, corporate communications, intellectual property, and new product planning.\n “We are excited to have Lee join the miRagen team and bring an extensive track record of experience across all aspects of business planning, licensing, and commercialization in the biotech industry. Adding Lee to the miRagen executive team puts us in a stronger position to realize the potential of our pipeline of proprietary RNA-targeted therapies in both near and long-term opportunities,” stated Dr. Marshall. “I am pleased to be joining the miRagen team at this exciting time in the company’s history. I believe the current pipeline offers a number of clinical and preclinical stage programs ready for continued development, as well as for potential partnerships and licensing opportunities with the potential to drive long-term shareholder value,” stated Ms. Rauch. Ms. Rauch has more than 25 years of experience in the biotech and pharmaceutical industries, helping build successful companies from pre-clinical stage to advanced clinical development. During this time, she has held several executive positions with Global Blood Therapeutics (NASDAQ: GBT), Onyx Pharmaceuticals, Nuon Therapeutics, POINT Biomedical, COR Therapeutics, and Syntex Corporation (Roche Bioscience). She has also served as a consultant to the biotech and pharmaceutical industry. Prior to joining miRagen, she was the Executive in Residence at Columbia Technology Ventures. Until 2015, she held the role of Chief Business Officer at GBT, where she oversaw overall business functions. Prior to GBT, she was President and CEO of Nuon Therapeutics, an auto-immune and inflammatory disease company. Before Nuon, she was the Interim Chief Business Officer and V.P. of Corporate Development at Onyx. Earlier in her career she was a founding member of McKinsey & Co.’s Pharmaceutical Practice. Ms. Rauch receiv...